» Articles » PMID: 26318273

Ammonia Impairs Glutamatergic Communication in Astroglial Cells: Protective Role of Resveratrol

Overview
Specialty Toxicology
Date 2015 Aug 31
PMID 26318273
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Ammonia is a key toxin in the precipitation of hepatic encephalopathy (HE), a neuropsychiatric disorder associated with liver failure. In response to ammonia, various toxic events are triggered in astroglial cells, and alterations in brain glutamate communication are common. Resveratrol is a polyphenolic compound that has been extensively studied in pathological events because it presents several beneficial effects, including some in the central nervous system (CNS). We previously described that resveratrol is able to significantly modulate glial functioning and has a protective effect during ammonia challenge in vitro. In this study, we addressed the mechanisms by which resveratrol can protect C6 astroglial cells from glutamatergic alterations induced by ammonia. Resveratrol was able to prevent all the effects triggered by ammonia: (i) decrease in glutamate uptake activity and expression of the EAAC1 glutamate transporter, the main glutamate transporter present in C6 cells; (ii) increase of glutamate release, which was also dependent on the activation of the Na(+)-K(+)-Cl(-) co-transporter NKCC1; (iii) reduction in GS activity and intracellular GSH content; and (iv) impairment of Na(+)K(+)-ATPase activity. Interestingly, resveratrol, per se, also positively modulated the astroglial functions evaluated. Moreover, we demonstrated that heme oxygenase 1 (HO1), an enzyme that is part of the cellular defense system, mediated some of the effects of resveratrol. In conclusion, the mechanisms of the putative protective role of resveratrol against ammonia toxicity involve the modulation of pathways and molecules related to glutamate communication in astroglial cells.

Citing Articles

Astrocyte dysfunction alters GABAergic communication and ammonia metabolism in the streptozotocin-induced sporadic Alzheimer's disease model.

Brezolin E, Gayger-Dias V, Da Silva V, Cigerce A, Schultz B, Sobottka T J Alzheimers Dis Rep. 2025; 8(1):1381-1393.

PMID: 40034350 PMC: 11863748. DOI: 10.1177/25424823241289036.


Modulation of brain energy metabolism in hepatic encephalopathy: impact of glucose metabolic dysfunction.

Prasad S, Acharjee A, Singh V, Trigun S, Acharjee P Metab Brain Dis. 2024; 39(8):1649-1665.

PMID: 39120853 DOI: 10.1007/s11011-024-01407-7.


Therapeutic Applications of Resveratrol in Hepatic Encephalopathy through Its Regulation of the Microbiota, Brain Edema, and Inflammation.

Kim Y, Song J J Clin Med. 2021; 10(17).

PMID: 34501267 PMC: 8432232. DOI: 10.3390/jcm10173819.


Sulforaphane Induces Glioprotection After LPS Challenge.

Bobermin L, Weber F, Dos Santos T, Bello-Klein A, Wyse A, Goncalves C Cell Mol Neurobiol. 2020; 42(3):829-846.

PMID: 33079284 PMC: 11441213. DOI: 10.1007/s10571-020-00981-5.


Role of serine protease inhibitor, ulinastatin, in rat model of hepatic encephalopathy: aquaporin 4 molecular targeting and therapeutic implication.

Abo El Gheit R, Atef M, Badawi G, Elwan W, Alshenawy H, Emam M J Physiol Biochem. 2020; 76(4):573-586.

PMID: 32794154 DOI: 10.1007/s13105-020-00762-0.